These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32054355)

  • 1. HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA).
    Cirillo F; Catellani C; Lazzeroni P; Sartori C; Tridenti G; Vezzani C; Fulghesu AM; Madeddu E; Amarri S; Street ME
    Gynecol Endocrinol; 2020 Jul; 36(7):588-593. PubMed ID: 32054355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
    Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
    Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
    Fruzzetti F; Capozzi A; Canu A; Lello S
    Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
    De Cicco S; Immediata V; Romualdi D; Policola C; Tropea A; Di Florio C; Tagliaferri V; Scarinci E; Della Casa S; Lanzone A; Apa R
    Gynecol Endocrinol; 2017 Sep; 33(9):698-701. PubMed ID: 28434274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
    Fruzzetti F; Fidecicchi T; Palla G; Gambacciani M
    Gynecol Endocrinol; 2020 Feb; 36(2):152-155. PubMed ID: 31317814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
    Nordio M; Basciani S; Camajani E
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5512-5521. PubMed ID: 31298405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model.
    Zhang Y; Li C; Zhang W; Zheng X; Chen X
    J Med Food; 2020 Apr; 23(4):375-387. PubMed ID: 32045334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
    Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A
    Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
    Cappelli V; Di Sabatino A; Musacchio MC; De Leo V
    Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
    Pustotina O; Myers SH; Unfer V; Rasulova I
    Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.
    Artini PG; Obino MER; Micelli E; Malacarne E; Vacca C; Papini F; Cela V
    Gynecol Endocrinol; 2020 Sep; 36(9):755-759. PubMed ID: 32157927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
    Artini PG; Di Berardino OM; Papini F; Genazzani AD; Simi G; Ruggiero M; Cela V
    Gynecol Endocrinol; 2013 Apr; 29(4):375-9. PubMed ID: 23336594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study.
    Rago R; Marcucci I; Leto G; Caponecchia L; Salacone P; Bonanni P; Fiori C; Sorrenti G; Sebastianelli A
    J Biol Regul Homeost Agents; 2015; 29(4):913-23. PubMed ID: 26753656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.
    Genazzani AD; Lanzoni C; Ricchieri F; Jasonni VM
    Gynecol Endocrinol; 2008 Mar; 24(3):139-44. PubMed ID: 18335328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study.
    Troisi J; Cinque C; Giugliano L; Symes S; Richards S; Adair D; Cavallo P; Sarno L; Scala G; Caiazza M; Guida M
    J Ovarian Res; 2019 Mar; 12(1):25. PubMed ID: 30904021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
    Stracquadanio M; Ciotta L; Palumbo MA
    Gynecol Endocrinol; 2018 Jun; 34(6):495-501. PubMed ID: 29265900
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Cirillo F; Catellani C; Sartori C; Lazzeroni P; Morini D; Nicoli A; Giorgi-Rossi P; Amarri S; La Sala GB; Street ME
    Gynecol Endocrinol; 2019 Oct; 35(10):842-846. PubMed ID: 30964354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome.
    Minozzi M; Costantino D; Guaraldi C; Unfer V
    Gynecol Endocrinol; 2011 Nov; 27(11):920-4. PubMed ID: 21417594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome.
    Donà G; Sabbadin C; Fiore C; Bragadin M; Giorgino FL; Ragazzi E; Clari G; Bordin L; Armanini D
    Eur J Endocrinol; 2012 Apr; 166(4):703-10. PubMed ID: 22223702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.